Skip to main content

Table 2 Clinical characteristics of patients with nontuberculous mycobacterial lung disease receiving inhaled amikacin therapy

From: The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases

Case

Sex

Species

MIC of CLA

(μg/mL)

Radiological pattern

Prior Treatment

Total treatment duration before AMK therapy (months)

Drugs at AMK initiation

Duration of AMK therapy (months)

Sputum conversion post-therapy

Radiological findings poet-therapy

#1

M

M.avium

0.25

FC

CLA, EMB

16

CLA, EMB

13

+

Improvement

#2

F

M.avium

0.5

NB + FC

CLA, RIP, EMB

4

CLA, RIP, EMB

7

−

No change

#3

M

M.avium

>32

NB

CLA, RIP, EMB

52

RIP, EMB, STFX

6

−

Worsening

#4

F

M.avium

0.5

NB

CLA, RIP, EMB

124

CLA, RIP, EMB

5

+

No change

#5

F

M.intracellulare

≦0.03

NB + FC

CLA, EMB

9

CLA, EMB

20

−

Worsening

#6

M

M.avium

0.5

NB

CLA, RIP, STFX, AMK div

110

CLA, RIP, STFX

1a

Unevaluable

Unevaluable

#7

F

M.avium

>32

NB + FC

RIP, STFX

16

RIP, STFX

< 1a

Unevaluable

Unevaluable

#8

F

M.avium

2

NB

CLA, RIP, EMB

43

CLA, RIP, EMB

36b

−

No change

#9

F

M.avium

>32

NB

RFB, MFLX

221

RFB, MFLX

6

−

Worsening

#10

F

M.avium

0.5

NB

CLA, RIP, EMB, STFX

86

CLA, RIP, EMB, STFX

6, 7c

−

No change

#11

F

M.abscessus

−

NB

EMB, STFX

29

EMB, STFX

24

+

Improvement

#12

F

M.avium

>32

NB + FC

CLA, EMB

99

CLA, EMB

7, 9c

+

Worsening

#13

F

M.avium

0.5

NB

CLA, RIP, STFX

72

CLA, RIP, STFX

6

−

No change

#14

F

M.avium

>32

NB + FC

RIP, EMB, STFX

145

RIP, EMB, STFX

6

+

Unchanged

#15

F

M.avium

>32

NB

RIP, EMB, STFX

81

RIP, EMB, STFX

13

+

Improvement

#16

F

M.avium

4

NB + FC

CLA, RIP, EMB

67

CLA, RIP, EMB

24

+

Improvement

#17

F

M.abscessus

−

NB + FC

CLA, STFX, DOXY

31

STFX, DOXY, DRPM

3a

Unevaluable

Unevaluable

#18

F

M.avium

>32

NB

EMB, STFX

55

EMB, STFX

6, <1c

−

No change

#19

F

M.avium

4

NB + FC

CLA, RIP, EMB

112

CLA, RIP, EMB

7

−

No change

#20

F

M.avium

0.125

NB + FC

CLA, RIP, EMB

13

CLA, RIP, EMB

12

+

Improvement

#21

F

M.abscessus

−

NB + FC

CLA, RIP, EMB

25

CLA, DOXY, DRPM

12

+

Improvement

#22

M

M.avium

0.125

NB

CLA, RIP, EMB, STFX

83

CLA, RIP, EMB, STFX

10

−

Worsening

#23

F

M.avium

>32

NB

CLA, RIP, EMB

131

RIP, EMB

6

−

No change

#24

F

M.avium

>32

NB + FC

RIP, EMB, STFX

106

RIP, EMB, STFX

7, 6c

−

No change

#25

F

M.avium

0.25

NB

CLA, RIP, EMB

46

CLA, RIP, EMB

9

+

Improvement

#26

F

M.avium

0.125

NB + FC

CLA, RIP, EMB

44

CLA, RIP, EMB

6

−

No change

  1. M male, F female, div intravenous drip
  2. CLA clarithromycin, EMB ethambutol, RIP rifampicin, RFB rifabutin, STFX sitafloxacin, DRPM doripenem, DOXY doxycycline, NB nodular bronchiectatic type, FC fibrocavitary type
  3. (under line); CLA resistance (CLA MIC ≥32 (μg/mL))
  4. aloss to follow-up
  5. bcurrent therapy is also being continued
  6. cinhaled AMK therapy was used again at some interval
  7. Sputum conversion ‘+’ denotes three consecutive negative sputum cultures during follow up